ArticleBMC health services research2026
From campaign to continuity: stakeholders' recommendations for integrating HPV vaccination into Nigeria's healthcare system.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor Human Papillomavirus (HPV) vaccination to be delivered effectively, countries must transition from campaign-based introduction to integration within the routine immunization schedule. While existing literature provides insights into the effectiveness of HPV campaigns and barriers to initial vaccine acceptance, there is a dearth of stakeholder-informed implementation research around the transition from campaign to routine delivery. This study aimed to explore the experiences and perspectives of key stakeholders involved in the HPV vaccine campaign in Nigeria to generate stakeholder-driven recommendations for the effective and sustainable integration of the vaccine into the country’s routine immunization schedule and strengthen national capacity for introducing and sustaining future new vaccines.
methodsThis study adopted a qualitative, exploratory research design. The research was conducted across nine Nigerian states, representing five of the six geopolitical zones. Participants were purposively sampled, encompassing 140 stakeholders (30 Key Informant Interviews, 110 In-depth Interviews). Data were collected using semi-structured interview guides, audio-recorded, transcribed verbatim, and thematically analysed.
resultsStakeholder recommendations emphasize that effectively integrating the HPV vaccine into routine immunization in Nigeria demands a multi-pronged strategy. This includes comprehensive strategies for awareness, engagement, and mobilization; continuous workforce training and motivation; robust data systems and reporting; effective management of misinformation; and intensification campaign. Additionally, early and thorough planning, fostering government ownership, optimizing operational logistics, ensuring consistent funding, and maintaining vaccine availability are critical. These insights provide valuable, transferable lessons for the introduction and sustained implementation of future vaccines.
conclusionThe transition of the Human Papillomavirus (HPV) vaccine from a campaign-driven approach to routine immunization in Nigeria represents a critical juncture, offering both significant challenges and unparalleled opportunities to strengthen the national health system. Policy priorities should include institutionalizing periodic intensification programs, strengthening community engagement, standardizing immunization data systems, securing sustainable financing, and enhancing primary healthcare infrastructure. By addressing these priorities, Nigeria can achieve equitable HPV vaccine coverage and strengthen its capacity for future vaccine initiatives, ensuring a lasting public health impact. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.